These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35192093)

  • 1. Pharmaceutical pricing dynamics in an internal reference pricing system: evidence from changing drugs' reimbursements.
    Costa E; Santos C
    Eur J Health Econ; 2022 Dec; 23(9):1497-1518. PubMed ID: 35192093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends and determinants of retail prescription drug costs.
    Teasdale B; Nguyen A; van Meijgaard J; Schulman KA
    Health Serv Res; 2022 Jun; 57(3):548-556. PubMed ID: 35211965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of pharmaceutical prices: evidence from a reference price reform in Denmark.
    Kaiser U; Mendez SJ; Rønde T; Ullrich H
    J Health Econ; 2014 Jul; 36():174-87. PubMed ID: 24879578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Price to Consumers of Generic Pharmaceuticals: Beyond the Headlines.
    Frank RG; Hicks A; Berndt ER
    Med Care Res Rev; 2021 Oct; 78(5):585-590. PubMed ID: 32468959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reference pricing with endogenous generic entry.
    Brekke KR; Canta C; Straume OR
    J Health Econ; 2016 Dec; 50():312-329. PubMed ID: 27350294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous versus exogenous generic reference pricing for pharmaceuticals.
    Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
    Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.
    Bian B; Gorevski E; Kelton CM; Guo JJ; Martin Boone JE
    J Manag Care Pharm; 2012 Sep; 18(7):506-15. PubMed ID: 22971204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public drug expenditure in the Republic of Ireland.
    Barry M; Usher C; Tilson L
    Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):239-45. PubMed ID: 20545588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More cost-sharing, less cost? Evidence on reference price drugs.
    Herr A; Stühmeier T; Wenzel T
    Health Econ; 2023 Feb; 32(2):413-435. PubMed ID: 36415146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia.
    Casanova-Juanes J; Mestre-Ferrandiz J; Espín-Balbino J
    Health Policy; 2018 Dec; 122(12):1310-1315. PubMed ID: 30389186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indication-wide drug pricing: Insights from the pharma market.
    Siegmeier F; Büssgen M
    J Pharm Policy Pract; 2022 Aug; 15(1):53. PubMed ID: 36038951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do generics offer significant savings to the UK National Health Service?
    Kanavos P
    Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competition and the Reference Pricing Scheme for pharmaceuticals.
    Ghislandi S
    J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
    Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
    Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994-2004?
    Håkonsen H; Horn AM; Toverud EL
    Health Policy; 2009 May; 90(2-3):277-85. PubMed ID: 19042052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.